Monte Rosa Therapeutics Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ____________ to ____________Commission File Number: 001-40522 Monte Rosa Therapeutics, Inc. (Exact name of registrant as specified in its charter) 84-3766197(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) 321 Harrison Avenue, Suite 900Boston, Massachusetts(Address of principal executive offices) 02118(Zip Code) Registrant’s telephone number, including area code: (617) 949-2643 Securities registered pursuant to Section 12(b) of the Act: TradingSymbol(s)GLUE Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☒ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 1, 2026, the registrant had84,479,418 shares of common stock, $0.0001 per share, outstanding. Special note regarding forward-looking statements This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements which are madepursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the or theSecurities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Allstatements other than statements of historical facts contained in this Quarterly Report are forward-looking statements.In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expects”,“intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “continue” or the negative of these termsor other comparable terminology. These statements are not guarantees of future results or performance and involvesubstantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to,statements about: •the initiation, timing, progress, results, costs, and any expectations and/or predictions of success of our currentand future research and development programs and preclinical studies, including our expectations for ourmolecular glue degraders, or MGDs, molecules, including our GSPT1-directed MGD MRT-2359, our out-licensedVAV1-directed MGD MRT-6160, our NEK7-directed MGDs, including MRT-8102, and our CDK2 and CCNE1MGDs; •the initiation, timing, progress, results, costs, and any expectations and/or predictions of success of our currentand any future clinical trials, including our clinical trials for our GSPT1-directed MGD MRT-2359, our NEK7directed MGD MRT-8102, and for our out-licensed VAV1 directed MGD MRT-6160, including statementsregarding the nature of or the timing for when any results of any clinical trials will become available; •our ability to continue to develop our proprietary discovery engine, called QuEENTM, and to expand our proteomicsand translational medicine capabilities; •the potential advantages of our discovery engine technology and product candidates; •the extent to which our scientific approach and discovery engine technology may target proteins that have beenconsidered undruggable or inadequately drugged; •our plans to submit Investigational New Drug, or IND applications to the U.S. Food and Drug Administration, orthe FDA for current and future product candidates; •the potential benefits of strategic collaborations and our ability to enter into strategic collaborations with thirdparties who have the expertise to enable us to further develop our biological t